These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32572987)

  • 1. The efficacy of onabotulinumtoxinA in patients with previous failed augmentation cystoplasty: Cohort series and literature review.
    Toia B; Pakzad MH; Hamid R; Wood DN; Greenwell TJ; Ockrim JL
    Neurourol Urodyn; 2020 Aug; 39(6):1831-1836. PubMed ID: 32572987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
    Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
    BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
    Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
    Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA.
    Shreck E; Gioia K; Lucioni A
    Curr Urol Rep; 2016 Apr; 17(4):27. PubMed ID: 26902621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of electromotive drug administration in delivering botulinum toxin a in children with neuropathic detrusor overactivity-outcomes of a pilot study.
    Koh C; Melling CV; Jennings C; Lewis M; Goyal A
    J Pediatr Urol; 2019 Oct; 15(5):552.e1-552.e8. PubMed ID: 31326328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA.
    Przydacz M; Golabek T; Chlosta P
    Adv Clin Exp Med; 2019 Apr; 28(4):555-567. PubMed ID: 30729759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
    Ghalayini IF; Al-Ghazo MA
    Neurourol Urodyn; 2007; 26(4):531-536. PubMed ID: 17330289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
    Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
    World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC; Kuo HC
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
    Naqvi S; Clothier J; Wright A; Garriboli M
    J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent? Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity.
    Ghalayini IF; Al-Ghazo MA; Elnasser ZA
    Int Urol Nephrol; 2009 Dec; 41(4):805-13. PubMed ID: 19184509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
    Chen SF; Kuo HC
    J Formos Med Assoc; 2015 Jul; 114(7):583-9. PubMed ID: 24262922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study.
    Denys P; Del Popolo G; Amarenco G; Karsenty G; Le Berre P; Padrazzi B; Picaut P;
    Neurourol Urodyn; 2017 Feb; 36(2):457-462. PubMed ID: 26756554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intradetrusor botox injection and augmentation cystoplasty trends among spina bifida patients at US freestanding children's hospitals.
    Vasdev R; Softness K; Cahill D; Panagides J; Logvinenko T; Saunders R; Bauer S; Estrada C; Wang HS
    J Pediatr Urol; 2024 Jun; 20(3):482.e1-482.e6. PubMed ID: 38402080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.